Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fiche publication
Date publication
août 2018
Journal
Cancer medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
Tous les auteurs :
Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J
Lien Pubmed
Résumé
The Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling pathway plays a key role in the systemic inflammatory response in many cancers, including colorectal cancer (CRC). This study evaluated the addition of ruxolitinib, a potent JAK1/2 inhibitor, to regorafenib in patients with relapsed/refractory metastatic CRC.
Mots clés
JAK1 protein tyrosine kinase, JAK2 protein tyrosine kinase, clinical trial, colorectal cancer, inflammation, ruxolitinib
Référence
Cancer Med. 2018 Aug 19;: